english.prescrire.org > Spotlight > 100 most recent

Spotlight

Every month, the subjects in Prescrire’s Spotlight.

100 most recent :  1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

Drugs for hepatitis C: it's time to slash prices!

The high prices of hepatitis C drugs are an obstacle to treatment for most of the people around the world who are infected by the virus.
1 December 2018

Avoid pregnancy during treatment with valproic acid or its derivatives

New measures have been taken in the European Union to prevent the exposure of fetuses to valproic acid and its derivatives.
1 December 2018

Drug-induced gynaecomastia

FEATURED REVIEW  Drug-related proliferation of male breast tissue generally subsides after discontinuation of the substance that caused it. This must be weighed against the potential disadvantages of stopping treatment or substituting another drug.
Full review (5 pages) available for download by subscribers.
1 November 2018

In the November issue of Prescrire International: Ending pharmaceutical sales representatives' access to hospitals and students

FREE DOWNLOAD In-person promotion of drugs to healthcare professionals by pharmaceutical sales representatives, known as pharmaceutical detailing, has been shown to influence doctors' prescribing behaviour. A US study looked at ways to limit this influence.
Full text available for free download.
1 November 2018

Alcohol dependence: the risks of high-dose baclofen

With high-dose baclofen, there is an increased risk of epilepsy, infection, myocardial infarction or suicidal thoughts.
1 November 2018

Denosumab (Prolia°) and osteoporosis: an increasingly unfavourable harm-benefit balance

Reports of sometimes serious adverse effects tilt the harm-benefit balance of denosumab in the treatment of osteoporosis.
1 November 2018

Venetoclax (Venclyxto°): another drug made available on the market too soon

Ventoclax inhibits a protein often present in abnormal lymphocytes in cases of chronic lymphocytic leukaemia. But does venetoclax extend the patient’s life span? We don’t know because we don’t have a comparative trial.
1 November 2018

  The 2018 "Prescrire Prize" is awarded in Paris to
  4 noteworthy books about health and healthcare

The recipients of the 2018 "Prescrire Prize" book awards were announced on 4 October 2018. The prize is awarded to works of particular interest to the general public and/or healthcare professionals.
04 October 2018

Bezlotoxumab (Zinplava°) and recurrence of C. difficile infection: No proven effect against serious complications, and cardiotoxicity

FEATURED REVIEW Given the serious complications associated with Clostridium difficile infection, treatment that safely reduces the risk of recurrences in high-risk patients would constitute a therapeutic advance. Bezlotoxumab's ability to deliver this advance has not been demonstrated. Full review (2 pages) available for download by subscribers.
1 October 2018

In the October issue of Prescrire International - Dexrazoxane in children: European disagreements and arbitration

FREE DOWNLOAD In 2017, dexrazoxane was re-approved in the European Union for use in children treated with high doses of anthracyclines. However, uncertainties remain.
Full text available for free download.
1 October 2018

1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90